Nextbiomedical Co Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nextbiomedical Co and similar public comparables like REPLOID Group, Atrium Therapeutics, Agenus, Outlook Therapeutics and more.

Nextbiomedical Co Overview

About Nextbiomedical Co

Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.


Founded

2014

HQ

South Korea

Employees

N/A

Financials (LTM)

Revenue: $13M
EBITDA: ($746K)

EV

$190M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nextbiomedical Co Financials

Nextbiomedical Co reported last 12-month revenue of $13M and negative EBITDA of ($746K).

In the same LTM period, Nextbiomedical Co generated $9M in gross profit, ($746K) in EBITDA losses, and had net loss of ($1M).

Revenue (LTM)


Nextbiomedical Co P&L

In the most recent fiscal year, Nextbiomedical Co reported revenue of $11M and EBITDA of $387K.

Nextbiomedical Co is unprofitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 3%, and net margin of (1%).

See analyst estimates for Nextbiomedical Co
LTMLast FY202320242025202620272028
Revenue$13M$11M$3M$6M$11M
Gross Profit$9M$8M$1M$4M$8M
Gross Margin69%70%43%61%70%
EBITDA($746K)$387K($4M)$3M$387K
EBITDA Margin(6%)3%(133%)41%3%
EBIT Margin(14%)(4%)(107%)(37%)(4%)
Net Profit($1M)($67K)($5M)$2M($209K)
Net Margin(10%)(1%)(154%)30%(2%)
Net Debt-$548K---

Financial data powered by Morningstar, Inc.

Nextbiomedical Co Stock Performance

Nextbiomedical Co has current market cap of $208M, and enterprise value of $190M.

Market Cap Evolution


Nextbiomedical Co's stock price is $25.33.

Nextbiomedical Co share price decreased by 5.7% in the last 30 days, and by 32.6% in the last year.

Nextbiomedical Co has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Nextbiomedical Co
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$190M$208M-0.5%-5.7%-36.7%-32.6%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nextbiomedical Co Valuation Multiples

Nextbiomedical Co trades at 14.3x EV/Revenue multiple, and (254.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Nextbiomedical Co

EV / Revenue (LTM)


Nextbiomedical Co Financial Valuation Multiples

As of July 19, 2026, Nextbiomedical Co has market cap of $208M and EV of $190M.

Nextbiomedical Co has a P/E ratio of (161.2x).

LTMLast FY202320242025202620272028
EV/Revenue14.3x17.2x57.9x29.6x17.2x
EV/EBITDAn/mn/m(43.6x)73.0xn/m
EV/EBIT(102.4x)n/m(54.1x)(79.1x)n/m
EV/Gross Profit20.6x24.5x134.1x48.6x24.5x
P/E(161.2x)n/m(41.1x)108.0xn/m
EV/FCF(77.5x)(148.7x)(66.9x)(172.4x)(148.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nextbiomedical Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nextbiomedical Co Margins & Growth Rates

Nextbiomedical Co grew revenue by 38% but EBITDA decreased by 490% in the last fiscal year.

In the most recent fiscal year, Nextbiomedical Co reported gross margin of 70%, EBITDA margin of 3%, and net margin of (1%).

See estimated margins and future growth rates for Nextbiomedical Co

Nextbiomedical Co Margins

Last FY202420252026202720282029
Gross Margin70%61%70%69%
EBITDA Margin3%41%3%(10%)
EBIT Margin(4%)(37%)(4%)(19%)
Net Margin(1%)30%(2%)(15%)
FCF Margin(12%)(17%)(12%)(22%)

Nextbiomedical Co Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth38%95%73%38%
Gross Profit Growth36%176%98%36%
EBITDA Growth(490%)(160%)(85%)(490%)
EBIT Growth509%(32%)(80%)509%
Net Profit Growth3346%(138%)(111%)998%
FCF Growth164%(61%)16%164%

Data powered by FactSet, Inc. and Morningstar, Inc.

Nextbiomedical Co Operational KPIs

Nextbiomedical Co's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nextbiomedical Co's Rule of X is 86% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Nextbiomedical Co
LTMLast FY202320242025202620272028
Rule of 4034%29%---
Bessemer Rule of X93%86%---
S&M Expenses to Revenue-7%14%7%7%
G&A Expenses to Revenue-3%4%3%3%
R&D Expenses to Revenue-46%98%69%46%
Opex to Revenue-74%150%98%74%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nextbiomedical Co Competitors

Nextbiomedical Co competitors include REPLOID Group, Atrium Therapeutics, Agenus, Outlook Therapeutics, Immunic, Medeze Group, Heartseed, Huons Co, Keros Therapeutics and Precision BioSciences.

Most Nextbiomedical Co public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
REPLOID Group35560.3x---
Atrium Therapeutics(3.1x)(3.0x)0.7x-
Agenus1.9x1.7x3.5x-
Outlook Therapeutics159.9x17.1x(3.6x)-
Immunic--(0.2x)-
Medeze Group6.4x6.3x18.7x18.8x
Heartseed8.8x16.6x81.2x-
Huons Co0.7x-5.0x-

This data is available for Pro users. Sign up to see all Nextbiomedical Co competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nextbiomedical Co

When was Nextbiomedical Co founded?Nextbiomedical Co was founded in 2014.
Where is Nextbiomedical Co headquartered?Nextbiomedical Co is headquartered in South Korea.
Is Nextbiomedical Co publicly listed?Yes, Nextbiomedical Co is a public company listed on Korea Exchange.
What is the stock symbol of Nextbiomedical Co?Nextbiomedical Co trades under 389650 ticker.
When did Nextbiomedical Co go public?Nextbiomedical Co went public in 2024.
Who are competitors of Nextbiomedical Co?Nextbiomedical Co main competitors include REPLOID Group, Atrium Therapeutics, Agenus, Outlook Therapeutics, Immunic, Medeze Group, Heartseed, Huons Co, Keros Therapeutics, Precision BioSciences.
What is the current market cap of Nextbiomedical Co?Nextbiomedical Co's current market cap is $208M.
What is the current revenue of Nextbiomedical Co?Nextbiomedical Co's last 12 months revenue is $13M.
What is the current revenue growth of Nextbiomedical Co?Nextbiomedical Co revenue growth (NTM/LTM) is 40%.
What is the current EV/Revenue multiple of Nextbiomedical Co?Current revenue multiple of Nextbiomedical Co is 14.3x.
Is Nextbiomedical Co profitable?No, Nextbiomedical Co is not profitable.
What is the current EBITDA of Nextbiomedical Co?Nextbiomedical Co has negative EBITDA and is not profitable.
What is Nextbiomedical Co's EBITDA margin?Nextbiomedical Co's last 12 months EBITDA margin is (6%).
What is the current EV/EBITDA multiple of Nextbiomedical Co?Current EBITDA multiple of Nextbiomedical Co is (254.8x).
What is the current FCF of Nextbiomedical Co?Nextbiomedical Co's last 12 months FCF is ($2M).
What is Nextbiomedical Co's FCF margin?Nextbiomedical Co's last 12 months FCF margin is (18%).
What is the current EV/FCF multiple of Nextbiomedical Co?Current FCF multiple of Nextbiomedical Co is (77.5x).
How many companies Nextbiomedical Co has acquired to date?Nextbiomedical Co hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Nextbiomedical Co has invested to date?Nextbiomedical Co hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Nextbiomedical Co

Lists including Nextbiomedical Co

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial